Compare CXT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXT | IRON |
|---|---|---|
| Founded | 1855 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.9B |
| IPO Year | 1994 | 2020 |
| Metric | CXT | IRON |
|---|---|---|
| Price | $54.00 | $75.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $73.00 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 680.6K | 572.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $3,374,900,000.00 | N/A |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $4.22 | $283.52 |
| P/E Ratio | $480.55 | ★ N/A |
| Revenue Growth | ★ 6.13 | N/A |
| 52 Week Low | $35.71 | $40.00 |
| 52 Week High | $69.00 | $99.50 |
| Indicator | CXT | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 70.62 | 52.69 |
| Support Level | $53.18 | $70.29 |
| Resistance Level | $56.16 | $82.65 |
| Average True Range (ATR) | 1.58 | 3.26 |
| MACD | -0.11 | -0.42 |
| Stochastic Oscillator | 91.73 | 32.98 |
Crane NXT Co is a industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters to its customers. It is a pioneer in proprietary micro-optics technology for securing physical products, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. The company operates in two segments which are Crane Payment Innovations (CPI) and Security and Authentication Technologies.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.